Ms Chong has over 21 years' experience in leading clinical and department development in oncology. She is Director of Cure Brain Cancer Foundation since April 2020.

Mr Hopper has over 20 years' experience in the management and funding of biotechnology and health care public companies both as chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas and on immune therapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.

Mr Walker has experience across the biotechnology and life sciences industry. His experience includes operational and leadership positions in biotechnology firms, capital markets track record from executing nearly 60 international and domestic corporate transactions, both as principal and advisor, and a detailed scientific understanding from a technical background in pharmacology. He is Chair of Risk Committee.

Dr Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). At GSK he leads technical and funding decisions in R&D as well as Discovery and Development in Oncology and in immuno-oncology, epigenetics, cell therapy, and synthetic lethality. Dr Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), Director on the Board of TCR2, Co-Founder and Director on the Board of Imugene, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Dr Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipitimumab). Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (former Antigenics). He is Member of Risk Committee.

Dr Russell has over 25 years' experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK.

Dr Eckstein has more than 15 years' venture capital experience in the biopharmaceutical industry and 10 years' operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at NM Capital. He is Member of Risk Committee.

-

-

-

-

-

-